相控序列的阵列交织快速生成

相控序列为一种性能优越的新型伪随机序列,长为(2~n-1)~2的PC序列可通过(2~n-1)~2的GMW序列和与相控序列相伴的交错序列交织生成。通过移位产生有限域元素和计算迹函数构造PC序列,分别产生了长为9, 49, 225, 961, 3 969, 16 129的PC序列,并验证了其性质。采用该方法由计算机模拟生成六万多个长为961的PC序列,时间小于12 s。     

碱、表面活性剂和聚合物为主的三元复合驱油体系相行为研究

通过研究不同浓度Na2 CO3、KPS存在的条件下复合驱油体系的相行为变化 ,找到了形成中相最佳区的条件 ,揭示了相行为与油水界面张力及表面活性剂在不同相间分配量大小的相关性 ,从临界胶束浓度变化对相态转变机理给予合理解释。     

位相、势和AB效应

本文阐明在量子力学中基本的物理实在是势 .波函数的相位与动量的空间积累和能量的时间积累有关 .相位和势是重要物理量     

Multiphase experiments in practice: A look back

Multiphase experiments are introduced and an overview of their design and analysis as it is currently practised is given via an account of their development since 1955 and a literature survey. Methods that are available for designing and analysing them are outlined, with an emphasis on making explicit the role of the model in their design. The availability of software and its use is described in detail. Overall, while multiphase designs have been applied in areas such as plant breeding, plant pathology, greenhouse experimentation, product storage, gene expression studies, and sensory evaluation, their deployment has been limited.     

Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle

Many new anticancer agents can be combined with existing drugs, as combining a number of drugs may be expected to have a better therapeutic effect than monotherapy owing to synergistic effects. Furthermore, to drive drug development and to reduce the associated cost, there has been a growing tendency to combine these as phase I/II trials. With respect to phase I/II oncology trials for the assessment of dose combinations, in the existing methodologies in which efficacy based on tumor response and safety based on toxicity are modeled as binary outcomes, it is not possible to enroll and treat the next cohort of patients unless the best overall response has been determined in the current cohort. Thus, the trial duration might be potentially extended to an unacceptable degree. In this study, we proposed a method that randomizes the next cohort of patients in the phase II part to the dose combination based on the estimated response rate using all the available observed data upon determination of the overall response in the current cohort. We compared the proposed method to the existing method using simulation studies. These demonstrated that the percentage of optimal dose combinations selected in the proposed method is not less than that in the existing method and that the trial duration in the proposed method is shortened compared to that in the existing method. The proposed method meets both ethical and financial requirements, and we believe it has the potential to contribute to expedite drug development.     

A simulation study of methods for selecting subgroup‐specific doses in phase 1 trials

Patient heterogeneity may complicate dose‐finding in phase 1 clinical trials if the dose‐toxicity curves differ between subgroups. Conducting separate trials within subgroups may lead to infeasibly small sample sizes in subgroups having low prevalence. Alternatively,it is not obvious how to conduct a single trial while accounting for heterogeneity. To address this problem,we consider a generalization of the continual reassessment method on the basis of a hierarchical Bayesian dose‐toxicity model that borrows strength between subgroups under the assumption that the subgroups are exchangeable. We evaluate a design using this model that includes subgroup‐specific dose selection and safety rules. A simulation study is presented that includes comparison of this method to 3 alternative approaches,on the basis of nonhierarchical models,that make different types of assumptions about within‐subgroup dose‐toxicity curves. The simulations show that the hierarchical model‐based method is recommended in settings where the dose‐toxicity curves are exchangeable between subgroups. We present practical guidelines for application and provide computer programs for trial simulation and conduct.     

CO-OFDM系统中基于线性预处理的新相位噪声抑制算法

针对相干光正交频分复用（coherent optical orthogonal frequency division multiplexing,CO-OFDM）系统中相位噪声引起的载波间干扰（inter-carrier interference,ICI）问题,提出了一种基于线性预处理的新判决反馈相位噪声抑制算法。该新算法改进了线性预处理部分,利用循环前缀与OFDM符号固有的相关性,在时域进行简单的线性组合运算,充分利用了OFDM符号中冗余信息。仿真分析表明,在激光器线宽为200 kHz且误码率（bit error rate, BER）为10－4时,与判决反馈相位噪声抑制算法和一次迭代的判决反馈相位噪声抑制算法相比,该新算法BER曲线的信噪比（signal to noise ratio,SNR）分别改善了3 dB和1 dB,有效地降低由ICI引起的错误平层。     

A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain

Two-stage designs offer substantial advantages for early phase II studies. The interim analysis following the first stage allows the study to be stopped for futility, or more positively, it might lead to early progression to the trials needed for late phase II and phase III. If the study is to continue to its second stage, then there is an opportunity for a revision of the total sample size. Two-stage designs have been implemented widely in oncology studies in which there is a single treatment arm and patient responses are binary. In this paper the case of two-arm comparative studies in which responses are quantitative is considered. This setting is common in therapeutic areas other than oncology. It will be assumed that observations are normally distributed, but that there is some doubt concerning their standard deviation, motivating the need for sample size review. The work reported has been motivated by a study in diabetic neuropathic pain, and the development of the design for that trial is described in detail.     

Identifying the most successful dose (MSD) in dose-finding studies in cancer

For a dose finding study in cancer, the most successful dose (MSD), among a group of available doses, is that dose at which the overall success rate is the highest. This rate is the product of the rate of seeing non-toxicities together with the rate of tumor response. A successful dose finding trial in this context is one where we manage to identify the MSD in an efficient manner. In practice we may also need to consider algorithms for identifying the MSD which can incorporate certain restrictions, the most common restriction maintaining the estimated toxicity rate alone below some maximum rate. In this case the MSD may correspond to a different level than that for the unconstrained MSD and, in providing a final recommendation, it is important to underline that it is subject to the given constraint. We work with the approach described in O'Quigley et al. [Biometrics 2001; 57(4):1018-1029]. The focus of that work was dose finding in HIV where both information on toxicity and efficacy were almost immediately available. Recent cancer studies are beginning to fall under this same heading where, as before, toxicity can be quickly evaluated and, in addition, we can rely on biological markers or other measures of tumor response. Mindful of the particular context of cancer, our purpose here is to consider the methodology developed by O'Quigley et al. and its practical implementation. We also carry out a study on the doubly under-parameterized model, developed by O'Quigley et al. but not     

A two phases queueing system with Bernoulli vacation schedule under multiple vacation policy

This paper deals with a single server Poisson arrival queue with two phases of heterogeneous service along with a Bernoulli schedule vacation model, where after two successive phases service the server either goes for a vacation with probability p (0≤p≤1) or may continue to serve the next unit, if any, with probability q(=1−p). Further the concept of multiple vacation policy is also introduced here. We obtained the queue size distributions at a departure epoch and at a random epoch, Laplace Stieltjes Transform of the waiting time distribution and busy period distribution along with some mean performance measures. Finally we discuss some statistical inference related issues.